Hepatitis C treatment eligibility among HIV–hepatitis C virus coinfected patients in Oregon: a population-based sample

References

• Adeyemi, O. M., Jensen, D., Attar, B., Ghaoui, R., Gallagher, M., Wolen, D., & Cotler, S. J. (2004). Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care and STDs, 18, 239–245. doi:10.1089/108729104323038919
   PubMed Web of Science ®Google Scholar
• Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., … Hellard, M. E. (2013). Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases, 57(Suppl. 2), S80–S89. doi:10.1093/cid/cit306
   PubMed Web of Science ®Google Scholar
• Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., & Snydman, D. R. (2001). Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases, 32, 492–497. doi:10.1086/318501
   PubMed Web of Science ®Google Scholar
• Blair, J. M., McNaghten A. D., Frazier, E. L., Skarbinski, J., Huang, P., & Heffelfinger, J. D. (2011). Clinical and behavioral characteristics of adults receiving medical care for HIV infection- medical monitoring project, United States, 2007. MMWR Surveillance Summaries, 60(11), 1–20.
   PubMedGoogle Scholar
• Butt, A. A., Khan, U. A., Shaikh, O. S., McMahon, D., Dorey-Stein, Z., Tsevat, J., & Lo Re, V., 3rd. (2009). Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clinical Trials, 10(1), 25–32. doi:10.1310/hct1001-25
   PubMed Web of Science ®Google Scholar
• Butt, A. A., McGinnis, K., Skanderson, M., & Justice, A. C. (2011). A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Research and Human Retroviruses, 27, 973–979. doi:10.1089/aid.2011.0004
   PubMed Web of Science ®Google Scholar
• Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., … Perronne, C. (2004). Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. Journal of the American Medical Association, 292, 2839–2848. doi:10.1001/jama.292.23.2839
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2013). HIV and Viral Hepatitis. Retrieved from http://www.cdc.gov/hepatitis/Populations/PDFs/HIVandHep-FactSheet.pdf
   Google Scholar
• Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., … van der Horst, C. (2004). Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. The New England Journal of Medicine, 351, 451–459. doi:10.1056/NEJMoa032653
   PubMed Web of Science ®Google Scholar
• Danta, M., Semmo, N., Fabris, P., Brown, D., Pybus, O. G., Sabin, C. A., … Klenerman, P. (2008). Impact of HIV on host-virus interactions during early hepatitis C virus infection. The Journal of Infectious Diseases, 197, 1558–1566. doi:10.1086/587843
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. (2011). EASL clinical practice guidelines: Management of hepatitis C virus infection. Journal of Hepatology, 55, 245–264. doi:10.1016/j.jhep.2011.02.023
   PubMed Web of Science ®Google Scholar
• Fleming, C. A., Tumilty, S., Murray, J. E., & Nunes, D. (2005). Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care. Clinical Infectious Diseases, 40(Suppl. 5), S349–S354. doi:10.1086/427452
   PubMed Web of Science ®Google Scholar
• Fultz, S. L., Justice, A. C., Butt, A. A., Rabeneck, L., Weissman, S., & Rodriguez-Barradas, M. (2003). Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clinical Infectious Diseases, 36, 1039–1046. doi:10.1086/374049
   PubMed Web of Science ®Google Scholar
• Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49, 1335–1374. doi:10.1002/hep.22759
   PubMed Web of Science ®Google Scholar
• Grebely, J., Raffa, J. D., Meagher, C., Duncan, F., Genoway, K. A., Khara, M., … Conway, B. (2007). Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology and Hepatology, 22, 1519–1525. doi:10.1111/j.1440-1746.2007.05032.x
   PubMed Web of Science ®Google Scholar
• Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., … Zeuzem, S. (2009). Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine, 360, 1839–1850. doi:10.1056/NEJMoa0807650
   PubMed Web of Science ®Google Scholar
• Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., … Zeuzem, S. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine, 364, 2405–2416. doi:10.1056/NEJMoa1012912
   PubMed Web of Science ®Google Scholar
• Kwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., … Albrecht, J. K. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. The Lancet, 376, 705–716. doi:10.1016/S0140-6736(10)60934-8
   PubMed Web of Science ®Google Scholar
• Marcellin, P., Chousterman, M., Fontanges, T., Ouzan, D., Rotily, M., Varastet, M., … Cacoub, P. (2011). Adherence to treatment and quality of life during hepatitis C therapy: A prospective, real-life, observational study. Liver International, 31, 516–524. doi:10.1111/j.1478-3231.2011.02461.x
   PubMed Web of Science ®Google Scholar
• Martín-Carbonero, L., Soriano, V., Valencia, E., García-Samaniego, J., López, M., & González-Lahoz, J. (2001). Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Research and Human Retroviruses, 17, 1467–1471. doi:10.1089/08892220152644160
   PubMed Web of Science ®Google Scholar
• Matthews, G., Kronberg I. J., & Dore, G. J. (2005). Treatment for hepatitis C virus infection among current drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), S325–S329. doi:10.1086/427448
   PubMed Web of Science ®Google Scholar
• McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., … Muir, A. J. (2009). Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. The New England Journal of Medicine, 360, 1827–1838. doi:10.1056/NEJMoa0806104
   PubMed Web of Science ®Google Scholar
• Mehta, S. H., Lucas, G. M., Mirel, L. B., Torbenson, M., Higgins, Y., Moore, R. D., … Sulkowski, M. S. (2006). Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS, 20, 2361–2369. doi:10.1097/QAD.0b013e32801086da
   PubMed Web of Science ®Google Scholar
• Restrepo, A., Johnson, T. C., Widjaja, D., Yarmus, L., Meyer, K., Clain, D. J., … Min, A. D. (2005). The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical center. Journal of Viral Hepatitis, 12(1), 86–90. doi:10.1111/j.1365-2893.2005.00548.x
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron, D., Lewden, C., Morlat, P., Bévilacqua, S., Jougla, E., Bonnet, F., … Chene, G. (2005). Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol. Journal of Hepatology, 42, 799–805. doi:10.1016/j.jhep.2005.01.022
   PubMed Web of Science ®Google Scholar
• Sylvestre, D. L., Litwin, A. H., Clements, B. J., & Gourevitch, M. N. (2005). The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment, 29, 159–165. doi:10.1016/j.jsat.2005.06.002
   PubMed Web of Science ®Google Scholar
• Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., … Dieterich, D. T. (2004). Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine, 351, 438–450. doi:10.1056/NEJMoa040842
   PubMed Web of Science ®Google Scholar
• U.S Department of Veterans Affairs. (2009). Chapter 6- assessing quality of care. Hepatitis C screening and diagnosis. Retrieved from http://www.hiv.va.gov/provider/policy/state-of-care/assessing-care.asp#S6X
   Google Scholar
• U.S Department of Veterans Affairs. (2012). Update on the management and treatment of hepatitis C virus infection. Retrieved from http://www.hepatitis.va.gov/provider/guidelines/2012HCV-index.asp
   Google Scholar
• Weber, R., Sabin, C. A., Friis-Moller, N., Reiss, P., El-Sadr, W. M., Kirk, O., … Lundgren, J. D. (2006). Liver-related deaths in persons infected with the human immunodeficiency virus the D:A:D study. Archives of Internal Medicine, 166, 1632–1641. doi:10.1001/archinte.166.15.1632
   PubMed Web of Science ®Google Scholar